Physician profile
Tim B Keller
NPI 1457311722
$862.12
in general payments reported to CMS, 2019-2025
18 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.36 · 2022: $71.80 · 2023: $194 · 2024: $247 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $149.94 | 2022-2025 | |
| Axsome Therapeutics, INC. | $100.83 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $76.54 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $75.92 | 2023-2025 | |
| Astellas Pharma US INC | $71.92 | 2024-2025 | Veozah, Padcev |
| Teva Pharmaceuticals USA, INC. | $63.47 | 2022-2024 | Austedo Xr |
| Lilly USA, LLC | $61.31 | 2022-2025 | Mounjaro, Zepbound |
| Dynavax Technologies Corporation | $47.89 | 2022-2025 | Heplisav-B |
| Mylan Specialty L.P. | $45.58 | 2023-2024 | Yupelri |
| Novo Nordisk INC | $30.54 | 2019-2025 | Ozempic |
| Abbott Laboratories | $22.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.22 | 2019 | |
| Glaxosmithkline, LLC. | $18.76 | 2023 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $17.21 | 2024 | Ingrezza |
| Viatris Specialty LLC | $16.85 | 2025 | Yupelri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.28 | 2024 | Farxiga |
| Sanofi Pasteur INC. | $14.05 | 2025 | |
| Merck Sharp & Dohme LLC | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.